News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial
Photo taken from medschool.vanderbilt.edu
Aug 30, 2024, 16:32

Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial

Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X:

“Congrats to Moshe Ornstein, MD and team for demonstrating the feasibility of an intermittent ipi/nivo approach in their Phase II trial, showing potential for prolonged treatment-free intervals.  Looking forward to more studies like this.”

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab

Authors: Moshe C. Ornstein, Laeth George, Wei Wei, C. Marcela Diaz-Montero, Pat Rayman, Allison Martin, Arnab Basu,  Kathryn E.
Beckermann, Amanda Nizam, Christopher E. Wee, Timothy D. Gilligan, Shilpa Gupta, Brian I. Rini
Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial
a

Additional information
Source: Katy Beckermann/X

Academic clinical trials Allison Martin Amanda Nizam Arnab Basu Brian I. Rini C. Marcela Diaz-Montero cancer Christopher E. Wee Kathryn E. Beckermann Katy Beckermann Laeth George Moshe C. Ornstein Moshe Ornstein OncoDaily Oncology Pat Rayman Shilpa Gupta Timothy D. Gilligan Vanderbilt University Medical Center Wei Wei
Special Coverage
Insight
Dec 22, 2024, 00:21
Eric J. Small: ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe